Physician profile
Patsy J Hudson
NPI 1902316607
$957.07
in general payments reported to CMS, 2019-2025
20 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.97 · 2022: $162 · 2023: $158 · 2024: $190 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.18 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $171.82 | 2022-2024 | Rexulti |
| Novo Nordisk INC | $58.54 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $52.93 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.30 | 2025 | Caplyta |
| Lilly USA, LLC | $40.43 | 2024-2025 | Zepbound, Mounjaro |
| Vertex Pharmaceuticals Incorporated | $40.28 | 2025 | |
| Mylan Specialty L.P. | $37.50 | 2021-2024 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $36.23 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $32.71 | 2025 | Arexvy, Shingrix |
| Amgen INC. | $30.11 | 2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $28.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $23.27 | 2025 | Watchman Access System |
| Sumitomo Pharma America, INC. | $21.98 | 2023 | Gemtesa |
| Dexcom, INC. | $20.23 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.81 | 2024 | |
| Esperion Therapeutics, INC. | $14.90 | 2025 | Nexletol |
| Pfizer INC. | $14.46 | 2025 | |
| Merck Sharp & Dohme LLC | $13.84 | 2025 | Capvaxive, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patsy Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.